Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M9466 + Carboplatin in Solid Tumors and ES-SCLC
NCT06719973Phase 1Withdrawn
- Sponsor
- EMD Serono
- Start
- May 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of M9466 in solid tumor and small cell lung cancer (SCLC) (3 arms), sponsored by EMD Serono. Primary endpoints: Treatment-Emergent Adverse Events and Dose-limiting Toxicity. Planned start May 2025; status: withdrawn.
02
Drugs
M9466
03
Conditions
solid tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06719973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719973.